2016
Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients
Nassar AF, Wisnewski AV, King I. Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients. Xenobiotica 2016, 47: 394-407. PMID: 27440490, DOI: 10.1080/00498254.2016.1201703.Peer-Reviewed Original ResearchConceptsPopulation pharmacokinetic analysisInter-patient variabilityPharmacokinetic analysisSignificant single-agent activitySingle-agent activityPopulation PK analysisVolume of distributionHigh inter-patient variabilityInter-occasion variabilityAlkylating agentCancer patientsTotal clearanceTotal body waterClinical trialsHematologic malignanciesPK analysisDosing cyclesOrgan functionSolid tumorsAntineoplastic alkylating agentCentral compartmentNONMEM analysisRapid clearancePatientsClearance
2011
Pathogenesis and Disease Mechanisms of Occupational Asthma
Lummus ZL, Wisnewski AV, Bernstein DI. Pathogenesis and Disease Mechanisms of Occupational Asthma. Immunology And Allergy Clinics Of North America 2011, 31: 699-716. PMID: 21978852, PMCID: PMC4683932, DOI: 10.1016/j.iac.2011.07.008.Peer-Reviewed Original ResearchConceptsOccupational asthmaWork-related lung diseaseMultifactorial pathogenetic mechanismsGenetic susceptibility factorsNonimmunologic mechanismsLung diseaseClinical managementInflammatory processPathogenetic mechanismsSusceptibility factorsDisease mechanismsCommon formAsthmaDiseasePatientsPathogenesis
2006
Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma
Ye YM, Kim CW, Kim HR, Kim HM, Suh CH, Nahm DH, Park HS, Redlich CA, Wisnewski AV. Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma. Journal Of Allergy And Clinical Immunology 2006, 118: 885-891. PMID: 17030242, DOI: 10.1016/j.jaci.2006.06.026.Peer-Reviewed Original Research
1998
Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120
Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, Hammer S, Koziel C, Trapnell C, Posner MR. Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120. AIDS Research And Human Retroviruses 1998, 14: 545-550. PMID: 9591708, DOI: 10.1089/aid.1998.14.545.Peer-Reviewed Original ResearchConceptsSingle doseHIV Type 1 Glycoprotein 120HIV-1-infected individualsHIV-1-infected cellsAnti-HIV-1 activityFunctional activityCD4-binding siteCD4 binding siteHuman monoclonal antibodyAbility of serumInfused antibodyQuantitative microcultureAntibody infusionEscalation studyFull functional activityGlycoprotein 120Primary isolatesHIV-1Immune responseSingle injectionGp120-CD4PatientsSite antibodiesCD4Spectrum of isolates
1994
Human monoclonal antibodies heterogeneously express a human cross-reactive idiotype associated with immune function in Schistosoma japonicum infection.
Wisnewski AV, Olds GR, Kresina TF. Human monoclonal antibodies heterogeneously express a human cross-reactive idiotype associated with immune function in Schistosoma japonicum infection. Human Antibodies 1994, 5: 178-82. PMID: 7756581.Peer-Reviewed Original ResearchConceptsHuman monoclonal antibodyEpstein-Barr virusSchistosoma japonicum infectionCross-reactive idiotypeJaponicum infectionImmune functionMonoclonal antibodiesSoluble egg antigenS. japonicum infectionWestern blot profilesSchistosomiasis patientsBarr virusEgg antigenHuman idiotypeIdiotype expressionReactive idiotypeMultiple antigensSerological analysisS. japonicumIdiotypeInfectionAntigenHeterogeneous expressionLevel of suppressionPatients